ARTRYA LIMITED — Capital/Financing Update 2025

Mar 31, 2025

==> picture [596 x 15] intentionally omitted <==

ASX ANNOUNCEMENT MARKET RELEASE

01 April 2025

Artrya secures contract with Lumus Imaging for use of Salix [®] Coronary Anatomy

Highlights

• Artrya secures commercial contract with Lumus Imaging for use of Salix[®] Coronary Anatomy platform for cardiovascular disease assessment at the point of care

• Lumus Imaging to first deploy Salix[®] at its St George centre in New South Wales, leveraging Salix[®] technology for patient diagnosis before expanding its use across Lumus Imaging's national network.

• Agreement represents a world-class collaboration as Lumus Imaging is one of only two imaging centres in the southern hemisphere equipped with the world-leading Photon Counting CT scanner.

• The 36-month contract will generate revenue through a Software-as-a-Service (SaaS) subscription model.

Artrya Limited (ASX:AYA), (‘Artrya’ or the ‘Company’), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, has secured a commercial contract with Lumus Imaging (Lumus) for the use of Salix[®] Coronary Anatomy platform with Lumus Imaging.

Lumus, one of Australia's leading diagnostic imaging providers, operates 150 Imaging centres nationally. Under a 36-month agreement, the Salix [®] Coronary Anatomy platform will first be integrated into Lumus Imaging's centre at St George Private Hospital, Sydney.

Lumus will leverage Salix [®] to accurately and efficiently detect critical markers, including high-risk plaque, from CT coronary angiogram (CTCA) scans generated by a Photon Counting CT scanner. Notably, Lumus Imaging is one of only two centres in the southern hemisphere equipped with this cutting-edge scanner, regarded as the most advanced CT technology globally.

The agreement between Lumus Imaging and Artrya represents a significant step forward in leveraging advanced technology for improved patient care. Artrya’s unique AI solution, combined with the world-leading Photon Counting CT Scanner, introduces a groundbreaking innovation with a revolutionary scanner that delivers significantly higher-definition images than traditional CT machines, while reducing exposure to harmful radiation. By integrating Artrya's AI capabilities with the Photon Counting CT Scanner at the St George centre, Lumus Imaging reinforces its commitment to cutting-edge innovation and providing world-class patient care.

Artrya Limited ACN 624 005 741 1257 Hay Street West Perth WA 6005 PO Box 567 West Perth WA 6872 www.artrya.com T: +61 8 6478 7816

Artrya CEO Mathew Regan said:

“Our contract with Lumus is a significant milestone for our commercial growth in Australia. We are pleased to be partnering with one of Australia's top imaging groups, placing our lifesaving, AI-driven technology in the hands of Australian clinicians to improve the diagnosis of the world’s number one killer, heart disease.

"We are just scratching the surface of the market for domestic diagnostic imaging. Having Salix [®] integrated into a key imaging centre such as St George with a world leading Photon Scanner, provides a significant entry into this important and growing sector in Australia.

“Lumus understands the benefits Salix [®] brings to accurately identify the true markers of heart disease on CTCA images at the point of care, even when using the world’s most advanced CT scanner, the Photon Counting CT. The accuracy of Salix [®] is further enhanced when used to assess images with significantly higher definitions than regular CTCA scans."

Dr Phil Lucas, CEO of Lumus Imaging said:

“We are thrilled to incorporate Salix [®] Coronary Anatomy as part of Lumus Imaging's diagnostic tools for cardiovascular disease. Salix [®] offers an evidence-based, personalised approach to how we diagnose patients at risk of cardiovascular disease. The layer of expertise Salix [®] provides, and particularly when paired with our Photon Counting CT scanner, ensures we continue to be at the cutting edge of heart disease diagnosis."

This announcement was approved by the Board.

For further information please contact:

Investor Enquiries: Media Relations: Danny Younis Rama Razy +61 420 293 042 +61 498 440 142 danny.younis@automicgroup.com.au rama.razy@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

Artrya Limited ACN 624 005 741 1257 Hay Street West Perth WA 6005 PO Box 567 West Perth WA 6872 www.artrya.com T: +61 8 6478 7816

About Lumus Imaging

Lumus Imaging is one of Australia’s largest diagnostic imaging providers, operating a network of 150 imaging centres across the country. Lumus Imaging offers a full suite of imaging modalities and services, including X- ray, ultrasound, computerised tomography (CT), mammography, magnetic resonance imaging (MRI), nuclear medicine, positron emission tomography (PET) and interventional radiology.

Our team of 2000 people comprises highly trained radiologists, radiographers, sonographers, nuclear medicine technologists, nurses, centre support and corporate staff who are passionate about caring for the health and wellbeing of our patients at every stage of life.

Each year, Lumus Imaging undertakes more than three million radiography examinations. Lumus Imaging is part of Healius Limited.

Appendix 1

Key Terms

Key Terms
Licensee	Lumus Imaging
Contract type	SAAS Software Licence Agreement
Product	The Software as a Medical Device known as Salix® CoronaryAnatomy
Territory	Australia
Contract term	36-month subscriptionTermination 30 days
Revenue Impact	The contract, valued at $180,000, will generate revenue through a through aSoftware-as-a-Service(SaaS)subscription model
Special terms	Artrya will commence invoicing the Licensee upon completion of integrationinto Licensee's imagingand reportingsystems

Artrya Limited ACN 624 005 741 1257 Hay Street West Perth WA 6005 PO Box 567 West Perth WA 6872 www.artrya.com T: +61 8 6478 7816